EX-FILING FEES 5 d805765dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Form S-8

(Form Type)

Catalyst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                         
    

Security

Type

 

Security

Class

Title

  Fee
Calculation 
or Carry
Forward
Rule
  Amount
Registered
(1) 
 

Proposed
Maximum
Offering

Price Per

Unit (2)

 

Maximum
Aggregate
Offering

Price

 

Fee

Rate

  Amount of 
Registration 
Fee
  Carry
Forward 
Form
Type
  Carry
Forward 
File
Number 
  Carry
Forward
Initial
Effective 
Date
  Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward
 
Newly Registered Securities
    Primary Offering of Securities:                            
                         

Fees to be

Paid

  Equity  

Common

Stock, par

value

$0.001 per

share (1)

  457(h)   3,000,000   $16.07 (2)   $48,210,000   —    $—    —    —    —    — 
                         

Fees to be

Paid

 

Total

Registration Fee

  —      3,000,000   $16.07 (2)   $48,210,000   0.00014760   $7,116   —    —    —    — 
 
Carry Forward Securities
                         

Carry

Forward

Securities

  —    —    —    —    —    —    —    —    —    —    —    — 
                   
    Total Offering Amounts     $48,210,000     $7,116          
                   
    Total Fees Previously Paid                  
                   
    Total Fee Offsets                  
                   
    Net Fee Due               $7,116                

 

(1)

Including such indeterminate amount of common stock as may be issued from time to time at indeterminate prices or upon conversion of common stock purchase options and restricted stock units, as the case may be.

(2)

Estimated solely for the purpose of calculating the registration fee which was computed in accordance with Rule 457(c) under the Securities Act of 1933, as amended, on the basis of the average of the high and low sales prices per share of the common stock as reported on the Nasdaq Capital Market on May 29, 2024.


Table 2: Fee Offset Claims and Sources

 

                       
    

Registrant

or Filer

Name

  Form
or
Filing
Type
  File
Number
  Initial
Filing
Date
  Filing
Date
 

Fee

Offset
Claimed 

  Security
Type
Associated
with Fee
Offset
Claimed
  Security
Title
Associated
with Fee
Offset
Claimed
  Unsold
Securities
Associated
with Fee
Offset
Claimed
  Unsold
Aggregate
Offering
Amount
Associated
with Fee
Offset
Claimed
  Fee Paid
with Fee
Offset
Source
 
Rule 457(p)
                       

Fee Offset

Claims

  Catalyst Pharmaceuticals, Inc.   S-8   —    —    —    —    —    —    —    —    — 
                       

Fee Offset

Sources

  Catalyst Pharmaceuticals, Inc.   S-8   —    —   

\

— 

  —    —    —    —    —    —